Skip to Content
Merck
  • Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency.

Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency.

iScience (2024-04-19)
Shuang Li, Ting Han
ABSTRACT

Most advanced colorectal cancer (CRC) patients cannot benefit from targeted therapy due to lack of actionable targets. By mining data from the DepMap, we identified FAM126B as a specific vulnerability in CRC cell lines exhibiting low FAM126A expression. Employing a combination of genetic perturbation and inducible protein degradation techniques, we demonstrate that FAM126A and FAM126B function in a redundant manner to facilitate the recruitment of PI4KIIIα to the plasma membrane for PI4P synthesis. Examination of data from TCGA and GTEx revealed that over 7% of CRC tumor samples exhibited loss of FAM126A expression, contrasting with uniform FAM126A expression in normal tissues. In both CRC cell lines and tumor samples, promoter hypermethylation correlated with the loss of FAM126A expression, which could be reversed by DNA methylation inhibitors. In conclusion, our study reveals that loss of FAM126A expression results in FAM126B dependency, thus proposing FAM126B as a therapeutic target for CRC treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-V5-Peroxidase antibody produced in mouse, clone V5-10, purified immunoglobulin, lyophilized powder
Pricing and availability is not currently available.